ABSTRACT
Valeriana wallichii referred to as Indian Valeriana has a family circle Valerianaceae commonly known as "Tagara". India, Nepal, and China are home to the important variety of the Valeriana genus. It is indigenous to India and can be found between 8000-10000 feet altitudes in the Himalayan region. Valeriana is a popular ethnobotanical remedy throughout Europe for relieving stress and improving sleep. Vital Central nervous system (CNS) activity is mirrored in the genuine Ayurvedic text-based content and declared as one of the handiest treatments with inside the remedy of neurosis and is powerful in pacifying the body ache (Vedanasathpana), chills (Sheetprashmana), and headaches (Shirah shoolprshmana). Additionally, it has been addressed in the Charaka Samhita as a remedy for snake poisoning. The rhizome and supporting tissues of valerian are used to treat insomnia, epilepsy, hypertension, and psychosomatic disorders. Important phytochemicals can reduce pain, manage stress, protect the brain from radiation, and fight off microbes. Hesperidin, the statutory potent flavonoid, 6-methylapigenin, and four new varieties of the iridoids Valeriotetrates B and C, 8-methylvalepotriate, and 1,5-dihydroxy-3,8-epoxyvalechlorine A are just a few of the naturally occurring active phytochemicals in the Valeriana wallichii.
ABSTRACT
Background: As per Ayurvedic classics, Ras?yana is a term used for unique therapeutic measures intended to improve cognition, memory, physical strength and delay the degenerative processes. Ayush Rasayana A & B are developed from extracts of herbs pertaining rasayana property. Aims & Objectives: To assess the safety and effectiveness of ‘Ayush Rasayana A and B’ in improving physical endurance, quality of life and cognition of elderly. Materials and Methods: This is an open label, single arm, multi-centre study among 256 apparently healthy elderly between 60?75 years. Ayush Rasayan A was given for 6 days and Ayush Rayana B for 180 days. The effect of the trial drug was seen on functional capacity, quality of life and cognitive function and, safety of the intervention was assessed through haematological and biochemical tests, clinical examination and incidence of adverse events. Results: Significant improvement in 6 minute walk test and HMSE score was observed at 187th as compared to baseline (p<0.0001). Quality of life of the participants especially in domains of physical health, social relationship and environment also improved at the end of intervention period (p<0.0001). The haematological and bio-chemical parameters showed no significant changes as compared to baseline and no adverse events were observed during the study. Conclusion: Ayush Rasayana A and Ayush Rasayana B, both were well tolerated by all the participants. This ayurvedic intervention can be safely given to apparently healthy elderly to improve their functionality, quality of life and cognition. However, a randomized controlled trial is warranted to substantiate the efficacy of this drug.
ABSTRACT
Signaling pathways play an intricate role in regulating the homeostasis of a normal cell and any chronically altered activity in such signaling pathways causes cancer. Such aberrantly activated Wnt and vanished p53 signaling contribute to the development of various carcinomas. Majority of cancer cells exhibit elevated production of reactive oxygen species (ROS) in an NADPH oxidases dependent manner that further enhances cellular damage. However, Nox family enzymes regulate various physiological functions; for instance, gene regulation, cellular signaling, host defense and cell differentiation. All of these processes get affected in cancer thereby signifying the role of Nox in controlling various signaling pathways such as Wnt and p53. Therefore, unraveling of complex signaling pathways underlying tumorigenesis is enforcing the development of next-generation anticancer drugs directed against specific molecular targets. This review provides an insight about Nox in regulation of Wnt and p53 pathway to govern the pathogenesis of cancer. Therefore, implementation of NOX inhibitors for inhibiting aberrant Wnt and p53 signaling could provide novel opportunities for therapeutic intervention.